These studies also revealed that fenofibrate, a PPAR-α agonist, approved by the Food and Drug Administration for the treatment of dyslipidemia [34] may increase the expression of both miR-301a and miR-454 leading to decreased ET-1 and PAI-1. Here, SERPINE1 is linked to metabolic syndrome.